microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2

He, Wei; Jiao, Feng; Zhang, Yan; Wang, Yuanyuan; Zang, Wenqiao

doi:10.1038/labinvest.2015.134

Cited by 37 publications

(29 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with AML with low expression levels ofmiR-186 had significantly lower rates of complete remission and shorter overall survival rates, compared with patients with a high level of miR-186 (20). He et al (21) reported that miR-186 was commonly downregulated in esophageal squamous cell carcinoma (ESCC), and was correlated with the level of differentiation, tumor-node-metastasis stage and lymph node metastasis in patients with ESCC. Liu et al (22) found that miR-186 was expressed at low levels in multiple myeloma tissues and cell lines, and miR-186 has been shown to be downregulated in oral squamous cell carcinoma (23), bladder cancer (24), colorectal neuroendocrine tumors (25), gastric cancer (26) and hepatocellular carcinoma (27).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-186 targets IGF-1R and exerts tumor-suppressing functions in glioma

Jiang

Wang

Fang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Glioma is the most common malignant brain tumor in adults and represents one of the most aggressive and life‑threatening types of cancer in humans. Increasing studies have revealed that microRNAs are abnormally expressed in various types of human cancer, and have oncogenic or tumor suppressive roles, which depend primarily on the type of cancer. The present study aimed to investigate the expression level and effects of microRNA‑186 (miR‑186) on glioma, and its underlying molecular mechanism. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis was performed to detect the expression of miR‑186 in glioma tissues and cell lines. Cell proliferation and invasion were assessed using MTT and cell invasion assays, respectively. Bioinformatics analysis and a luciferase reporter assay were performed to identify insulin‑like growth factor 1 receptor (IGF‑1R) as a novel target gene of miR‑186. The mRNA expression level of IGF‑1R was also measured using RT‑qPCR analysis. The association between miR‑186 and the expression of IGF‑1R was evaluated using Spearman's correlation anal-ysis. Furthermore, the regulatory effects of miR‑186 on the mRNA and protein expression of IGF‑1R were determined using RT‑qPCR and western blot analyses. Finally, the biological effects of the underexpression IGF‑1R on glioma cells were investigated. The results showed that miR‑186 was significantly downregulated in glioma tissues and cell lines. Inducing the expression of miR‑186 suppressed glioma cell proliferation and invasion. IGF‑1R was confirmed as a direct target gene of miR‑186. In addition, the mRNA expression of IGF‑1R was upregulated and inversely correlated with that of miR‑186 in glioma tissues. The effects of IGF‑1R‑knockdown on glioma cell proliferation and invasion were similar to the effects induced by the overexpression of miR‑186. These findings demonstrated that miR‑186 acted as a tumor suppressor by targeting IGF‑1R in glioma, suggesting miR‑186 may be a potential therapeutic target for the treatment of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-186 targets IGF-1R and exerts tumor-suppressing functions in glioma

Jiang

Wang

Fang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…MiR-186 inhibited the proliferation, migration, and invasion of glioma stem cells and promoted apoptosis via targeting XIAP and PAK7, thus regulating the expression levels of downstream target proteins such as caspase 3, BAD, cyclin D1, and MARK2 (42). Moreover, miR-186 suppressed cell proliferation and induced apoptosis by targeting either: MAP4K3 in hepatocellular carcinoma (34), NEK2 in gastric cancer cells (38), SKP2 in esophageal squamous cell carcinoma cells (45), SHP2 in oral squamous cell carcinoma cells (46), or targeting DDX43 (also known as HAGE, a cancer/testis antigen) in CML cells (49). In addition, miR-186 suppressed the proliferation, migration, invasiveness, and angiogenesis by targeting ST6GAL2 in follicular thyroid carcinoma cells (47), or targeting ATAD2 in retinoblastoma cells (51), and inhibited autophagy by targeting the autophagy-related proteins Atg7 and Beclin1 in glioma microvascular endothelial cells (8).…”

Section: Mir-186 As a Tumor Suppressor Mirnamentioning

confidence: 99%

The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA

et al. 2020

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of small non-coding RNAs which regulate gene expression at post-transcriptional level. Alterations of miR-186 expression were demonstrated in numerous cancers, shown to play a vital role in oncogenesis, invasion, metastasis, apoptosis, and drug resistance. MiR-186 was documented as a tumor suppressor miRNA in the majority of studies, while conflicting reports verified miR-186 as an oncomir. The contradictory role in cancers may impede the application of miR-186, as well as other dual-functional miRNAs, as a diagnostic and therapeutic target. This review emphasizes the alterations and functions of miR-186 in cancers and discusses the mechanisms behind the contradictory findings. Among these, target abundance and dose-dependent effects of miR-186 are highlighted. The paper aims to review the challenges involved in developing diagnostic and therapeutic strategies for cancer treatment based on dual-functional miRNAs.

show abstract

“…As a potential plasma biomarker for the diagnosis of acute pulmonary embolism, miR-134 is also reported to be up-regulated in patients with acute coronary syndrome (ACS) [25][26][27]. miR-186, which is previously reported to serve as a circulating biomarker for certain cancers [28,29] and modulate apoptosis in several kinds of cells [30,31], may also facilitate the diagnosis of ACS [26,32]. Although all these miRNAs were not cardiac-enriched miRNAs, preliminary evidence from a recent miRNA microarray analysis revealed that the expression of miR-19b, miR-134 and miR-186 were up-regulated in patients with AMI compared to controls [33].…”

Section: Introductionmentioning

confidence: 99%

Circulating MiR-19b-3p, MiR-134-5p and MiR-186-5p are Promising Novel Biomarkers for Early Diagnosis of Acute Myocardial Infarction

Wang¹,

Zhao²,

Liu³

et al. 2016

Cell Physiol Biochem

116

103

View full text Add to dashboard Cite

Background/Aims: Recent studies have shown that circulating microRNAs (miRNAs) are emerging as promising biomarkers for cardiovascular diseases. This study aimed to determine whether miR-19b-3p, miR-134-5p and miR-186-5p can be used as novel indicators for acute myocardial infarction (AMI). Methods: To investigate the kinetic expression of the three selected miRNAs, we enrolled 18 patients with AMI and 20 matched controls. Plasma samples were collected from each participant, and total RNA was extracted. Quantitative real-time PCR and ELISA assays were used to investigate the expression of circulating miRNAs and cardiac troponin I (cTnI), respectively. Plasma samples from another age- and gender-matched cohort were collected to investigate the impact of medications for AMI on the expression of the selected miRNAs. Results: Levels of plasma miR-19b-3p, miR-134-5p and miR-186-5p were significantly increased in early stage of AMI. Plasma miR-19b-3p and miR-134-5p levels reached peak expression immediately after admission (T0), whereas miR-186-5p achieved peak expression at 4 h after T0. All of these times were earlier than the peak for cTnI (8 h after T0). In addition, all three miRNAs were positively correlated with cTnI. Receiver Operating Characteristic (ROC) analysis indicated that each single miRNA showed considerable diagnostic efficiency for predicting AMI. Furthermore, combining all three miRNAs in a panel increased the efficiency of distinguishing between patients with AMI and controls. Moreover, we found that heparin and medications for AMI did not impact the expression of these circulating miRNAs. Conclusion: Circulating miR-19b-3p, miR-134-5p and miR-186-5p could be considered promising novel diagnostic biomarkers for the early phase of AMI.

show abstract

microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2

Cited by 37 publications

References 38 publications

MicroRNA-186 targets IGF-1R and exerts tumor-suppressing functions in glioma

MicroRNA-186 targets IGF-1R and exerts tumor-suppressing functions in glioma

The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA

Circulating MiR-19b-3p, MiR-134-5p and MiR-186-5p are Promising Novel Biomarkers for Early Diagnosis of Acute Myocardial Infarction

Contact Info

Product

Resources

About